INSUBCONTINENT EXCLUSIVE:
Hyderabad: The phase 3 trials of Covishield vaccine are being carried out on 1,600 participants at 15 centres in India
The vaccine is being developed by Pune-based Serum Institute of India (SII) and Indian Council of Medical Research (ICMR).Development of
Covishield started at SII Pune Laboratory with a master seed from Oxford University / Astra Zeneca
ICMR has funded clinical trial sites in India while SII is taking care of other expenses being incurred on development of the vaccine
Phase 3 clinical trials will provide data on safety and efficacy of Covishield vaccine
Testing on different populations in the country allows for a better understanding of how the vaccine works on various segments of people in
Results of the trials have been positive, says SII, expressing confidence that the vaccine will turn out to be a realistic solution for the
Evaluation of data by scientists across the world shows Covishield is by far the most advanced vaccine.SII has already manufactured 40
million doses of the vaccine under the at-risk manufacturing and stockpiling license from DCGI
Buoyed by latest technology and well-equipped facilities, SII has continually proven its research and manufacturing prowess
institute and ICMR coming together testifies the importance of public-private institutes coming together for scaling up efforts to contain
